Sakar Healthcare
SAKARNSE

Sakar Healthcare

₹885.2540.85 (4.84%)1D
1D
1W
1M
3M
6M
1Y
3Y
5Y
All
Create Stock SIPAutomate your investments in this
Overview
Technicals
News
Events

Performance

Today’s low
845.05
Today’s high
911.05
52 week low
311.00
52 week high
960.00
Open price
850.20
Previous close
844.40
Live volume
2,01,126
Lower circuit
760.00
Upper circuit
928.80

Fundamentals

Market Cap
₹1,879Cr
ROE
9.40%
P/E Ratio(TTM)
52.06
EPS(TTM)
16.22
P/B Ratio
5.79
Dividend Yield
0.00%
Industry P/E
37.76
Book Value
145.82
Debt to Equity
0.17
Face Value
10

Financial performance

Quarterly
Yearly
All Financials
JUN '26
Revenue (Cr)
₹74.51
+4.55%
Profit (Cr)
₹10.28
-6.72%
020406080
Jun '25
Sep '25
Dec '25
Mar '26
Jun '26
Revenue growthValue
1Y (TTM)+40%
3Y CAGR+11%
Profit growthValue
1Y (TTM)+120%
3Y CAGR+5%

About

Sakar Healthcare is a prominent player within India's pharmaceutical industry, distinguished by its vertically integrated manufacturing capabilities, particularly in the field of oncology. The company's vision is to become a global healthcare organization built on the three pillars of people, partnership, and performance to deliver world-class healthcare solutions. Its mission focuses on strengthening core competencies to be the preferred choice for partnerships and exploring new market opportunities to expand its product range. The company operates state-of-the-art facilities to produce both Active Pharmaceutical Ingredients (APIs) and finished formulations, ensuring quality control across the value chain. Its four manufacturing plants create a wide range of dosage forms, which include oral liquids, solids, injectables, and dry powder inhalers. With a strong export focus supported by a global distribution network, the company successfully serves customers in over 60 countries around the world.;
CEO/MD
Mr. Sanjay S. Shah
Founded in
2004
NSE symbol
SAKAR

Shareholding Pattern

Jun '26
Mar '26
Dec '25
Sep '25
Jun '25
Promoters
52.86%
Retail And Others
47.14%

Similar stocks

StockMkt price (1D)52 week performanceMarket capP/E ratioP/B ratio
PfizerPFIZER
₹4,823.90
+22.60 (0.47%)
L
    H
    21,954.5729.865.22
    ₹824.65
    -9.30 (1.12%)
    L
      H
      20,666.2631.24.38
      ₹8,100.00
      +41.50 (0.51%)
      L
        H
        20,225.13107.8523.17
        ₹1,354.70
        -20.50 (1.49%)
        L
          H
          19,062.8628.634.88
          Livesquawk
          Sakar Healthcare Q1 revenue surged 38% YoY to ₹730M vs ₹527M.
          Livesquawk
          Sakar Healthcare signs 40th deal with Zydus Lifesciences for oncology in GCC, emerging markets. Company filed 23 MAs in EU, gained 5 approvals, developed 21 APIs, and focuses on integration.
          Livesquawk
          Sakar Healthcare projects FY27 as a key year with stronger exports driving growth. Rising oncology volumes are expected to further support Sakar Healthcare's growth.
          Livesquawk
          Sakar Healthcare Q4 EBITDA rises to ₹262M, up from ₹157M YoY. EBITDA margin improves to 36.9% from 31.3% YoY.
          2026
          24
          Jul
          Quarterly Result
          Release date
          12
          May
          Annual Result
          Release date
          5
          Feb
          Quarterly Result
          Release date
          2025
          7
          Nov
          Quarterly Result
          Release date
          Events calendar
          View upcoming events in other stocks